Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Am J Alzheimers Dis Other Demen ; 35: 1533317520976761, 2020.
Article in English | MEDLINE | ID: covidwho-975841

ABSTRACT

By incorporating appropriate drug(s) into lipid (biobased) nanocarriers, one obtains a combination therapeutic for dementia treatment that targets certain cell-surface scavenger receptors (mainly class B type I, or "SR-BI") and thereby crosses the blood-brain barrier. The cardiovascular risk factors for dementia trigger widespread inflammation -- which lead to neurodegeneration, gradual cognitive/memory decline, and eventually (late-onset) dementia. Accordingly, one useful strategy to delay dementia could be based upon nanotargeting drug(s), using lipid nanocarriers, toward a major receptor class responsible for inflammation-associated (cytokine-mediated) cell signaling events. At the same time, the immune response and excessive inflammation, commonly observed in the very recent human coronavirus (COVID-19) pandemic, may accelerate the progression of brain inflammatory neurodegeneration-which increases the probability of post-infection memory impairment and accelerating progression of Alzheimer's disease. Hence, the proposed multitasking combination therapeutic, using a (biobased) lipid nanocarrier, may also display greater effectiveness at different stages of dementia.


Subject(s)
COVID-19/complications , Cognitive Dysfunction/complications , Dementia/virology , SARS-CoV-2/pathogenicity , COVID-19/virology , Cognitive Dysfunction/virology , Dementia/complications , Dementia/epidemiology , Disease Progression , Humans , Inflammation/complications , Inflammation/virology
SELECTION OF CITATIONS
SEARCH DETAIL